See a healthcare professional if you have any symptoms that worry you. If your health professional thinks that you may have astrocytoma, you'll likely be referred to a specialist. This specialist might be a cancer doctor, called an oncologist. You also may see a surgeon who specializes in operating on the brain, called a neurosurgeon.
Because appointments may be quick, it helps to come prepared. Here's some information that may help you get ready.
What you can do
When you make the appointment, ask if there's anything you need to do ahead of time, such as not eating before a specific test. Make a list of:
-
Your symptoms, even ones that don't seem related.
-
Key personal information, including major stresses, recent life changes and family medical history.
-
All medicines, vitamins or supplements you take, including the doses.
-
Questions you'd like to ask.
Take a trusted family member or friend along, if possible, to help you remember the information you're given.
For astrocytoma, some basic questions to ask your healthcare professional include:
- Do I have cancer?
- If the tumor isn't cancerous, do I still need to have it removed?
- Do I need more tests?
- What are my treatment options?
- What are the potential risks or side effects for these treatment options?
- Will any of these treatments cure my cancer?
- Can I have a copy of my pathology report?
- How much time can I take to consider my treatment options?
- Are there brochures or other printed materials that I can take with me? What websites do recommend?
- What would happen if I decide not to have treatment?
Don't hesitate to ask any other questions you have.
What to expect from your doctor
Your healthcare professional is likely to ask you several questions, such as:
- When did your symptoms begin?
- Do your symptoms come and go, or are they constant?
- How severe are your symptoms?
- What, if anything, seems to improve your symptoms?
- What, if anything, appears to worsen your symptoms?
What is the survival rate for the different grades of astrocytoma?
-
Grade 1, also called pilocytic, is usually cured with surgery. The five-year survival rate is around 96%.
-
Grade 2, also called diffuse, astrocytomas have a median survival of about 7 to 8 years.
-
Grade 3, also called anaplastic, astrocytomas have a median survival of about five years.
-
Grade 4, also called glioblastoma, astrocytomas have a median survival of about 14 to 15 months.
How does IDH-mutant status change life expectancy?
- An
IDH
mutation is linked with longer survival and better response to therapy compared with
IDH-wild-type tumors.
- For grade 2 disease, a change to the
IDH1
gene is specifically linked with longer survival and has a better outlook than
IDH wild type.
What is the prognosis for pilocytic astrocytoma in children?
Pilocytic astrocytoma (grade 1) in children is slow growing and often cured with surgery. The five-year survival rate is about 96%.
Anaplastic astrocytoma (grade 3): Factors linked to longer survival
Some people with anaplastic astrocytoma, also called grade 3, live much longer than the average five-year survival. In general, people with
IDH-mutant tumors, who are younger, recover well from surgery, and receive both chemotherapy and radiation, are the most likely to have long-term survival.
Several factors can help improve outcomes:
-
More complete tumor removal. When surgeons can safely remove most or all the tumor, people tend to live longer. The exact amount removed often makes a big difference.
-
Combined treatment. Using surgery followed by both radiation and chemotherapy gives the best survival rates for high-grade tumors.
-
Favorable tumor genetics.
Tumors with certain gene changes, such as an
IDH
or
MGMT gene change, tend to grow more slowly and respond better to treatment.
-
Younger age and good overall health. Younger people and those with fewer neurological symptoms at diagnosis tend to do better.
Astrocytoma treatment is personalized. Surgery is usually first, followed by radiation or chemotherapy or both based on the tumor's grade and genes. Some people also may receive targeted therapy. Supportive care, also called palliative care, can start early to control symptoms and protect quality of life. New options, such as gene-targeted medicines and immunotherapy, are being tested in clinical trials and may expand choices over time.